Table 4. Baseline and Change at Week 12 in Body Composition Parameters by Whole Body MRI.
| Variable | rhGH/Rosiglitazone | Rosiglitazone | rhGH | Double Placebo | P-value* | ||||
| Entry (n = 20) | Change at week 12 (n = 20) | Entry (n = 18) | Change at week 12 (n = 15) | Entry (n = 14) | Change at week 12 (n = 11) | Entry (n = 17) | Change at week 12 (n = 16) | ||
| VAT, L | 5.14 (2.74) | −1.13a (1.41) | 4.73 (2.01) | −0.19b (0.69) | 5.29 (2.29) | −1.15c (0.81) | 5.40 (1.88) | −0.04 (0.9) | 0.0012 |
| SAT, L | 22.69 (8.59) | −0.11 (3.33) | 20.98 (8.61) | 0.74 (1.86) | 26.41 (8.83) | −0.38 (1.23) | 24.46 (9.52) | −0.03 (2.64) | 0.89 |
| TAT, L | 31.99 (9.97) | −1.39 (4.08) | 30.12 (6.33) | 0.01 (1.49) | 35.13 (7.97) | −0.93 (1.88) | 32.20 (7.22) | −0.10 (3.25) | 0.53 |
| SM, L Median (Q1, Q3) | 27.12 (22.82, 34.59) | 0.70e (−0.09, 1.55) | 26.16 (23.10, 28.74) | −0.34f (−1.17, 0.23) | 30.36 (26.34, 33.95) | 1.11g (−0.46, 2.48) | 25.49 (23.58, 31.04) | −0.27 (−1.29, 0.53) | 0.014 |
Data are expressed as mean (standard deviation).
*
One-way ANCOVA (done on rank-transformed data for SM). rhGH x rosiglitazone interaction term was not statistically significant for any variables in two-way ANCOVA.
a
P = 0.003,
b
P = 0.91,
c
P = 0.01,
e
P = 0.08,
f
P = 0.99,
g
P = 0.05 compared to double placebo group.
Abbreviations: L, liter. Q1 (1st quartile), Q3 (3rd quartile). rhGH, recombinant human growth hormone; VAT, visceral adipose tissue volume; SAT, subcutaneous adipose tissue volume; TAT, total adipose tissue volume; SM, skeletal muscle.